Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vsee Health (VSEE) EBITDA Margin (2023 - 2025)

Vsee Health filings provide 3 years of EBITDA Margin readings, the most recent being 78.15% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 15922.0% to 78.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 21.04%, a 58062.0% increase, with the full-year FY2025 number at 21.04%, up 57534.0% from a year prior.
  • EBITDA Margin hit 78.15% in Q4 2025 for Vsee Health, up from 51.69% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 78.15% in Q4 2025 to a low of 1737.85% in Q3 2024.
  • Median EBITDA Margin over the past 3 years was 51.69% (2025), compared with a mean of 185.43%.
  • Biggest five-year swings in EBITDA Margin: crashed -171320bps in 2024 and later soared 168616bps in 2025.
  • Vsee Health's EBITDA Margin stood at 7.74% in 2023, then crashed by -948bps to 81.07% in 2024, then skyrocketed by 196bps to 78.15% in 2025.
  • The last three reported values for EBITDA Margin were 78.15% (Q4 2025), 51.69% (Q3 2025), and 66.51% (Q2 2025) per Business Quant data.